Stanford University HIV Drug Resistance Database - A curated public database designed to represent, store, and analyze the divergent forms of data underlying HIV drug resistance.

Clinical Trial Datasets

ACTG 302 clinical trial
References
Shulman, NS, Hughes MD, Winters MA, Shafer RW, Zolopa AR, Hellmann NS, Bates M, Whitcomb JM, Katzenstein DA. Subtle Decreases in Stavudine Phenotypic Susceptibility Predict Poor Virologic Response to Stavudine Monotherapy in Zidovudine-Experienced Patients. JAIDS. 2002 Oct 1;31(2):121-7.
Katzenstein, DA, Hughes MD, Albrecht M, Liou SH, Murphy R, Balfour H, Para M, Hammer S. AIDS Clinical Trials Group 302 Study Team. Virologic and CD4 Cell Response to Zidovudine or Zidovudine and Lamivudine Following Didanosine Treatment of Human Immunodeficiency Virus Infection. AIDS Res Hum Retroviruses. 2001 Feb 10;17(3):203-10.
Sequences
Nucleotide sequences in fasta format
ACTG302_PR_fasta.txt,   ACTG302_RT_fasta.txt
Composite alignment (of sequences at baseline)
ACTG302_PR_composite.html,   ACTG302_RT_composite.html
List of sequences with stop codon, ambiguity codon and unusual residues
ACTG302_PR_QA.txt,   ACTG302_RT_QA.txt

Method: Direct PCR, Dideoxy terminator sequencing
Sample: Plasma
Timing: Following study

Browse
Integrated view of ARV, genotypes, RNA and CD4 on 47 patients
Dataset
This dataset was created on 47 patients for whom sequences and ARV histories are available and contains files with treatment, mutations, RNA levels and CD4 counts.
Note on Dataset
These 47 patients belong to the subjects in the arm randomized to be treated with AZT, 3TC, ddI.
One patient without RNA level provided was excluded from the provided data: Ptid 29458.